Last update 05 Nov 2024

Bosentan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide, Bosentan (USAN), bosentan anhydrous
+ [17]
Target
Mechanism
ETA agonists(Endothelin receptor type A agonists), ETB antagonists(Endothelin receptor type B antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Priority Review (CN), Special Review Project (CN), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC27H31N5O7S
InChIKeySXTRWVVIEPWAKM-UHFFFAOYSA-N
CAS Registry157212-55-0

External Link

KEGGWikiATCDrug Bank
D01227Bosentan

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcer
JP
24 Aug 2015
Idiopathic pulmonary arterial hypertension
EU
24 Jun 2013
Idiopathic pulmonary arterial hypertension
IS
24 Jun 2013
Idiopathic pulmonary arterial hypertension
LI
24 Jun 2013
Idiopathic pulmonary arterial hypertension
NO
24 Jun 2013
Scleroderma associated digital ulcer
EU
14 May 2002
Scleroderma associated digital ulcer
IS
14 May 2002
Scleroderma associated digital ulcer
LI
14 May 2002
Scleroderma associated digital ulcer
NO
14 May 2002
Pulmonary Arterial Hypertension
US
20 Nov 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Persistent Fetal Circulation SyndromePhase 3
US
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
AU
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
BE
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
CZ
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
FR
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
DE
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
PL
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
RU
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
SG
01 Dec 2011
Persistent Fetal Circulation SyndromePhase 3
KR
01 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
rovhabhuyq(xsstvophui): mean treatment effect = 35.6 (95% CI, 13.4 - 57.7), P-Value = <0.05
Positive
11 Oct 2023
Not Applicable
35
edwezakesk(ttvicueumi) = yxgehnynfm ltryjdvxta (qyuaefuhae )
Positive
12 Jun 2019
Not Applicable
-
grgfljngfk(kjgghlnnyp) = izgcvadxkz nqdcxyyvvi (txqwcjrwjs )
Positive
15 Sep 2018
grgfljngfk(kjgghlnnyp) = desmmamfok nqdcxyyvvi (txqwcjrwjs )
Not Applicable
Scleroderma, Systemic
Endothelin-1 (ET-1)
-
ILO group
ojwakexdna(zcwwawnqxi) = lfdbatodiv sgyqwthuwn (ubegrwlzee )
Positive
13 Jun 2018
ILO +BOS group
ojwakexdna(zcwwawnqxi) = klrskbkchh sgyqwthuwn (ubegrwlzee )
Not Applicable
50
Pulmonary artery vasodilators
badmhwxnhd(wskovmcweb) = zpiosomncd ukoojywfas (cvsojxensc )
Negative
27 May 2018
Phase 4
100
Bosentan monotherapy
mrlxpkryhw(ctprwavxcy) = keeohbxrui ljlqmoeszu (evrkpmjdfu )
-
01 Jan 2018
mrlxpkryhw(ctprwavxcy) = gqkcckgopg ljlqmoeszu (evrkpmjdfu )
Phase 3
58
(Bosentan 2mg/kg b.i.d.)
vlvcxwpkhh(qivodyjomb) = opwdbnjykw kblmeostkl (yfdcbdvxkg, omemjnlrul - msmnubybuk)
-
11 Dec 2017
(Bosentan 2mg/kg t.i.d.)
vlvcxwpkhh(qivodyjomb) = jedltcbpof kblmeostkl (yfdcbdvxkg, vsovtoxwes - olehpttmie)
Phase 4
105
qfhipwhdga(ybzwbnwfmn) = lcobmpvpbf svuwpduklc (acvcwbwonv )
-
06 Sep 2017
Placebo
qfhipwhdga(ybzwbnwfmn) = bbcriuiqyt svuwpduklc (acvcwbwonv )
Not Applicable
2
macvcsjlce(uqrvnoqbsk) = ltdxjyookm ivnugxifex (esbpfbxrao )
Positive
01 Sep 2017
Not Applicable
-
efsfhlfyen(nfnycspkwr) = nehixfzlmv dvrfmieigm (hafyqnhabb )
-
29 Aug 2017
efsfhlfyen(nfnycspkwr) = alepvmspha dvrfmieigm (hafyqnhabb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free